Sartorius Biostat STR Generation 3 for Emerson's DeltaV

Technology company Emerson has collaborated with Sartorius to natively integrate the former’s Biostat STR Generation 3 family of bioreactors with Emerson’s DeltaV distributed control system (DCS). The Biostat STR Generation 3 for Emerson’s DeltaV is a pre-engineered solution that delivers intuitive connectivity for accelerating and simplifying the process of bringing therapies that improve patient quality of life to market.

A manufacturing plant’s DCS provides critical automation of operations for fast, safe production, but life sciences companies often struggle to connect process equipment to their plant’s automation system because engineering and configuring equipment is complex and time-consuming. Biostat STR Generation 3, natively integrated with a plant’s DeltaV DCS, eliminates this complexity for one of the most frequently used components of biopharmaceutical manufacturing.

The bioreactors are specifically designed and pre-engineered with DeltaV components from the ground up by Sartorius, while the configuration toolkit developed by Emerson and Sartorius has a library of templates that provide standardised configuration. Using the library, teams can integrate bioreactors into their control system quickly and easily out of the box. Commercial manufacturing sites can expect to save up to 80% of their equipment integration time, helping them take advantage of the enhanced features and diagnostics inherent in the DeltaV DCS quickly and easily. The increased automation reduces the need for manual operation, which should increase quality and speed up time to market.

The integrated bioreactors are built with technologies, including DeltaV Electronic Marshalling with CHARMs devices, to reduce wiring and configuration work during installation. The bioreactors can integrate seamlessly with Emerson’s DeltaV PK Controller as well as S-Series and M-Series controllers. Built-in templates provide standardised configurations for the most common uses, allowing teams to use standard setups out of the box to bring operations online rapidly and safely and allow them to change those operations quickly to meet shifting market needs.

The easy configuration and integration of the bioreactors helps life sciences manufacturers build a connected plant, moving closer to autonomous operations. Plants will also gain the ability to scale more easily, as installation techniques can be quickly and intuitively replicated across multiple process areas or even multiple facilities across the globe.